A Phase 2/3 interventional study of BHV-3500 (zavegepant) and Placebo in Migraine, sponsored by Pfizer. Terminated at 116 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-27.
Sponsored by Pfizer · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing zavegepant in Migraine Disorders — 4 open to participants now, 4 under way, none of them phase 3. zavegepant · Migraine Disorders.
Among the 12 studies testing zavegepant in Migraine Disorders, this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 3 in phase 2/3, and was the 4th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →4 of the 12 studies testing zavegepant in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States
Ages 6–11
Mayo Clinic · Sites in United States
Ages 18+
American Center for Psychiatry and Neurology
Ages 18+
By country, each count listing its studies:
zavegepant: first FDA approval 2023 (ZAVZPRET). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 6 · Phase 4 2
First in 2019; this study’s year is marked. 1 started in 2021.
This study's enrollment of 1,753 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 225 across the 12 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 5 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 6th largest by enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2021, is one of 5 in phase 2/3, and was the 19th registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing zavegepant in Migraine Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06401642Mayo ClinicEffectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications | 2027-03 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
| NCT06995729PfizerA Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine | 2027-08-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies testing zavegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of
Headache Disorders, 3rd Edition, including the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zavegepant 200mg oral soft gel capsule.
Drug: BHV-3500 (zavegepant)
Matching placebo 200mg oral soft gel capsule.
Drug: Placebo
Zavegepant 100mg oral soft gel capsule.
Drug: BHV-3500 (zavegepant)
Matching placebo 100mg oral soft gel capsule.
Drug: Placebo
BHV-3500 (zavegepant) softgel capsule.
Matching placebo softgel capsule.
Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)
A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of migraine headache). A qualified migraine headache was defined as migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A. \>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived as follows: 28\*(total number of migraine days through Month 3\[Weeks 1 to 12\] in on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3\[Weeks 1 to 12\] in the on-DBT efficacy analysis period).
Time frame: Observation Phase: 28 days prior to randomization and baseline; Entire DBT Phase: 12 weeks (Week 1 through 12)
Percentage of Participants With >= 50 % Reduction in Number of Moderate to Severe Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)
A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of following criteria (A and/or B): A. \>=2 of following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived as follows: 28\*(total number of migraine days through Month 3\[Weeks 1 to 12\] in the on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3\[Weeks 1 to 12\] in on-DBT efficacy analysis period).
Time frame: Entire DBT Phase: 12 weeks (Week 1 through 12)
Mean Change From Observation Phase in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase
A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A.\>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\* (total number of migraine days in the month\[Week 9 to 12\])/(total number of eDiary efficacy data days in the month\[Week 9 to 12\]).
Time frame: Observation Phase: 28 days prior to randomization and baseline; DBT Phase: last 4 weeks (Week 9 through 12)
Mean Change From Observation Phase in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase
A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A. \>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in the on-DBT efficacy analysis period as follows: 28\* (total number of migraine days in the month\[Week 1 to 4\])/ (total number of eDiary efficacy data days in the month\[Week 1 to 4\]).
Time frame: Observation Phase: 28 days prior to randomization and baseline; DBT Phase: first 4 weeks (Week 1 through 4)
Mean Number of Acute Migraine -Specific Medication Days Per Month Over Entire DBT Phase (Weeks 1 to 12)
Acute migraine (AM)-specific medication day was defined as any calendar day on which the participant took an acute migraine-specific medication during aura or to treat a headache. Acute migraine-specific medications were triptans and ergotamine. The number of acute migraine-specific medication days per month were prorated to 28 days and derived as follows: 28 \* (total number of acute migraine-specific medication days through Month 3 \[Week 1 to 12\] in the on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3 \[Week 1 to 12\] in the on-DBT efficacy analysis period).
Time frame: Entire DBT Phase: 12 weeks (Week 1 through 12)
Mean Change From Baseline in the Migraine-specific Quality of Life Questionnaire (MSQ) v 2.1 Restrictive Role Function Domain Score at Week 12
MSQ v 2.1 is 14-item questionnaire that assessed impact of treatment on participant-reported quality of life across 3 domains: role function-restrictive, preventive, and emotional function. Restrictive role function domain consists of 7 items that describe how migraine limits one's daily social, work-related activities. Participants respond to items using a 6-point scale ranging from 1 (none of the time) to 6 (all of the time), which are assigned scores of 1 to 6, respectively. Response from each item of restrictive role function domain were added providing a possible raw score range of 7 (no impairment) to 42 (maximum impairment). Raw score range of restrictive role function domain was then transformed to a 0 (no impairment) to 100 (maximum impairment), higher scores = higher impairment.
Time frame: DBT Phase: Baseline (before dose on Day 1), Week 12
Mean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12
MIDAS is a retrospective, participant-reported, 5-item questionnaire that measured headache related disability as lost days due to headache from paid work or school, household work and non-work activities over past 3-months. The total score is calculated as the sum of item scores to all 5 questions on a scale of 0 (no disability) to 90 (maximum disability) resulting into overall possible MIDAS total score (range from 0 (no disability) to 450 (maximum disability). Higher scores = more severe disability.
Time frame: DBT Phase: Baseline (before dose on Day 1), Week 12
Number of Participants With Moderate or Severe Adverse Events (AEs): DBT Phase
AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. AEs included both SAEs and all non-SAEs. Severity: Moderate=Alleviated with additional specific therapeutic intervention, interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe= Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.
Time frame: DBT Phase: During 12 weeks of treatment
Number of Participants With Serious Adverse Events (SAEs): DBT Phase
AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.
Time frame: DBT Phase: During 12 weeks of treatment
Number of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
Time frame: DBT Phase: During 12 weeks of treatment
Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities: DBT Phase
Laboratory tests included eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets; albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, bilirubin, calcium, cholesterol, potassium, sodium, triglycerides, uric acid, urinalysis, urine protein, creatine kinase (CK), creatinine, glomerular filtration rate (GFR), glucose, glucose fasting, lactate dehydrogenase, low density lipoprotein (LDL) Cholesterol, LDL Cholesterol. Number of participants with grade 3 to 4 laboratory test abnormalities were evaluated in this outcome measure. Only rows which included at least 1 participant in any reporting group with grade 3 to 4 abnormality were reported in this outcome measure. As per Common Terminology Criteria for Adverse Events (CTCAE version 5.0) Grade 3= severe and Grade 4= life-threatening or disabling.
Time frame: DBT: During 12 weeks of treatment
Number of Participants With Moderate or Severe AEs: OLE Phase
AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. AEs included both SAEs and all non-SAEs. Severity: Moderate=Alleviated with additional specific therapeutic intervention, interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe= Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.
Time frame: OLE: During 52 weeks of treatment
Number of Participants With SAEs: OLE Phase
AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.
Time frame: OLE: During 52 weeks of treatment
Number of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
Time frame: OLE: During 52 weeks of treatment
Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities: OLE Phase
Laboratory tests included eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets; albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, bilirubin, calcium, cholesterol, potassium, sodium, triglycerides, uric acid, urinalysis, urine protein, creatine kinase (CK), creatinine, glomerular filtration rate (GFR), glucose, glucose fasting, lactate dehydrogenase, low density lipoprotein (LDL) Cholesterol, LDL Cholesterol. Number of participants with grade 3 to 4 laboratory test abnormalities were evaluated in this outcome measure. Only rows which included at least 1 participant in any reporting group with grade 3 to 4 abnormality were reported in this outcome measure. As per Common Terminology Criteria for Adverse Events (CTCAE version 5.0) Grade 3= severe and Grade 4= life-threatening or disabling.
Time frame: OLE: During 52 weeks of treatment
Percentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: DBT Phase
Elevations of AST or alanine aminotransferase (ALT) \> 3 \*upper limit of normal (ULN) concurrent with total bilirubin (TBL) \> 2 \*ULN (elevations on the same laboratory collection date) were included.
Time frame: DBT: Over 12 weeks of treatment
Percentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: OLE Phase
Elevations of AST or ALT \> 3 \* ULN concurrent with TBL \> 2 \*ULN were defined as elevations on the same collection date.
Time frame: OLE: Over 52 weeks of treatment
Number of Participants With Hepatic-related AEs by Intensity: DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. AEs by intensity: Mild: Transient and may require only minimal treatment or therapeutic intervention. Event did not interfere with activities of daily living. Moderate: Alleviated with additional specific therapeutic intervention. Event interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe: Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.
Time frame: DBT Phase: During 12 weeks of treatment
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
Time frame: DBT Phase: During 12 weeks of treatment
Number of Participants With Hepatic-related AEs by Intensity: OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. AEs by intensity: Mild: Transient and may require only minimal treatment or therapeutic intervention. Event did not interfere with activities of daily living. Moderate: Alleviated with additional specific therapeutic intervention. Event interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe: Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.
Time frame: OLE: Over 52 weeks of treatment
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
Time frame: OLE: Over 52 weeks of treatment
| Milestone | Zavegepant 100 mg (OLE/DBT) | Zavegepant 200 mg (OLE/DBT) | Placebo (DBT)/ Zavegepant 100 mg (OLE) | Placebo (DBT)/ Zavegepant 200 mg (OLE) |
|---|---|---|---|---|
| Started | 178 | 180 | 88 | 88 |
| Treated | 173 | 175 | 86 | 88 |
| Completed | 144 | 134 | 69 | 64 |
| Not completed | 34 | 46 | 19 | 24 |
| Withdrew: Adverse event | 1 | 5 | 3 | 4 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 7 | 1 | 3 |
| Withdrew: Non-compliance | 1 | 0 | 1 | 2 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 2 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 15 | 16 | 5 | 9 |
| Withdrew: Withdrawal by subject | 6 | 12 | 7 | 6 |
| Withdrew: Randomized but not treated | 5 | 5 | 2 | 0 |
| Milestone | Zavegepant 100 mg (OLE/DBT) | Zavegepant 200 mg (OLE/DBT) | Placebo (DBT)/ Zavegepant 100 mg (OLE) | Placebo (DBT)/ Zavegepant 200 mg (OLE) |
|---|---|---|---|---|
| Started | 105 | 94 | 50 | 49 |
| Treated | 105 | 94 | 50 | 49 |
| Completed | 34 | 34 | 22 | 17 |
| Not completed | 71 | 60 | 28 | 32 |
| Withdrew: Adverse event | 3 | 4 | 2 | 0 |
| Withdrew: Lost to follow-up | 8 | 4 | 3 | 4 |
| Withdrew: Non-compliance | 2 | 2 | 0 | 1 |
| Withdrew: Other | 0 | 2 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 2 | 0 |
| Withdrew: Study terminated by sponsor | 41 | 37 | 17 | 19 |
| Withdrew: Withdrawal by subject | 16 | 8 | 3 | 7 |
| Withdrew: Not reported | 0 | 2 | 0 | 0 |
| Withdrew: Failure to meet continuation criteria | 0 | 0 | 1 | 1 |
| Milestone | Zavegepant 100 mg (OLE/DBT) | Zavegepant 200 mg (OLE/DBT) | Placebo (DBT)/ Zavegepant 100 mg (OLE) | Placebo (DBT)/ Zavegepant 200 mg (OLE) |
|---|---|---|---|---|
| Started | 154 | 162 | 47 | 48 |
| Completed | 124 | 131 | 41 | 38 |
| Not completed | 30 | 31 | 6 | 10 |
| Withdrew: Lost to follow-up | 5 | 9 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 7 | 6 | 3 | 4 |
| Withdrew: Not reported | 18 | 15 | 1 | 4 |
A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of migraine headache). A qualified migraine headache was defined as migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A. \>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived as follows: 28\*(total number of migraine days through Month 3\[Weeks 1 to 12\] in on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3\[Weeks 1 to 12\] in the on-DBT efficacy analysis period).
| Migraine Days per Month | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Placebo Pooled (DBT) |
|---|---|---|---|
| Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12) | -7.0 (-8.10 to -5.92) | -6.3 (-7.45 to -5.10) | -5.6 (-6.80 to -4.37) |
A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of following criteria (A and/or B): A. \>=2 of following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived as follows: 28\*(total number of migraine days through Month 3\[Weeks 1 to 12\] in the on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3\[Weeks 1 to 12\] in on-DBT efficacy analysis period).
| Percentage of participants | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Placebo Pooled (DBT) |
|---|---|---|---|
| Percentage of Participants With >= 50 % Reduction in Number of Moderate to Severe Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12) | 56.1 (47.7 to 65.1) | 46.6 (37.8 to 55.4) | 40.0 (31.4 to 48.5) |
A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A.\>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\* (total number of migraine days in the month\[Week 9 to 12\])/(total number of eDiary efficacy data days in the month\[Week 9 to 12\]).
| Migraine Days per Month | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Placebo Pooled |
|---|---|---|---|
| Mean Change From Observation Phase in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase | -7.8 (-9.11 to -6.59) | -7.2 (-8.56 to -5.83) | -6.8 (-8.22 to -5.38) |
A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A. \>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in the on-DBT efficacy analysis period as follows: 28\* (total number of migraine days in the month\[Week 1 to 4\])/ (total number of eDiary efficacy data days in the month\[Week 1 to 4\]).
| Migraine Days per Month | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Placebo Pooled (DBT) |
|---|---|---|---|
| Mean Change From Observation Phase in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase | -5.7 (-6.89 to -4.51) | -5.1 (-6.26 to -3.87) | -3.9 (-5.10 to -2.72) |
Acute migraine (AM)-specific medication day was defined as any calendar day on which the participant took an acute migraine-specific medication during aura or to treat a headache. Acute migraine-specific medications were triptans and ergotamine. The number of acute migraine-specific medication days per month were prorated to 28 days and derived as follows: 28 \* (total number of acute migraine-specific medication days through Month 3 \[Week 1 to 12\] in the on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3 \[Week 1 to 12\] in the on-DBT efficacy analysis period).
| AM-specific Medication Days per Month | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Placebo Pooled (DBT) |
|---|---|---|---|
| Mean Number of Acute Migraine -Specific Medication Days Per Month Over Entire DBT Phase (Weeks 1 to 12) | 2.4 (1.43 to 3.43) | 3.0 (1.91 to 4.17) | 3.2 (1.94 to 4.46) |
MSQ v 2.1 is 14-item questionnaire that assessed impact of treatment on participant-reported quality of life across 3 domains: role function-restrictive, preventive, and emotional function. Restrictive role function domain consists of 7 items that describe how migraine limits one's daily social, work-related activities. Participants respond to items using a 6-point scale ranging from 1 (none of the time) to 6 (all of the time), which are assigned scores of 1 to 6, respectively. Response from each item of restrictive role function domain were added providing a possible raw score range of 7 (no impairment) to 42 (maximum impairment). Raw score range of restrictive role function domain was then transformed to a 0 (no impairment) to 100 (maximum impairment), higher scores = higher impairment.
| Scores on a scale | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Placebo Pooled (DBT) |
|---|---|---|---|
| Mean Change From Baseline in the Migraine-specific Quality of Life Questionnaire (MSQ) v 2.1 Restrictive Role Function Domain Score at Week 12 | 24.5 (19.10 to 29.83) | 20.6 (14.63 to 26.61) | 20.5 (14.92 to 26.12) |
MIDAS is a retrospective, participant-reported, 5-item questionnaire that measured headache related disability as lost days due to headache from paid work or school, household work and non-work activities over past 3-months. The total score is calculated as the sum of item scores to all 5 questions on a scale of 0 (no disability) to 90 (maximum disability) resulting into overall possible MIDAS total score (range from 0 (no disability) to 450 (maximum disability). Higher scores = more severe disability.
| Scores on a scale | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Placebo Pooled (DBT) |
|---|---|---|---|
| Mean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12 | -26.8 (-35.81 to -17.79) | -27.1 (-36.62 to -17.61) | -17.9 (-31.36 to -4.34) |
AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. AEs included both SAEs and all non-SAEs. Severity: Moderate=Alleviated with additional specific therapeutic intervention, interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe= Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.
| Participants | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Zavegepant Pooled (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Placebo Pooled (DBT) |
|---|---|---|---|---|---|---|
| Number of Participants With Moderate or Severe Adverse Events (AEs): DBT Phase | 20 | 25 | 45 | 13 | 9 | 22 |
AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.
| Participants | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Zavegepant Pooled (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Placebo Pooled (DBT) |
|---|---|---|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs): DBT Phase | 1 | 1 | 2 | 0 | 1 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
| Participants | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Zavegepant Pooled (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Placebo Pooled (DBT) |
|---|---|---|---|---|---|---|
| Number of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase | 2 | 5 | 7 | 3 | 4 | 7 |
Laboratory tests included eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets; albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, bilirubin, calcium, cholesterol, potassium, sodium, triglycerides, uric acid, urinalysis, urine protein, creatine kinase (CK), creatinine, glomerular filtration rate (GFR), glucose, glucose fasting, lactate dehydrogenase, low density lipoprotein (LDL) Cholesterol, LDL Cholesterol. Number of participants with grade 3 to 4 laboratory test abnormalities were evaluated in this outcome measure. Only rows which included at least 1 participant in any reporting group with grade 3 to 4 abnormality were reported in this outcome measure. As per Common Terminology Criteria for Adverse Events (CTCAE version 5.0) Grade 3= severe and Grade 4= life-threatening or disabling.
| Participants | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Zavegepant Pooled (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Placebo Pooled (DBT) |
|---|---|---|---|---|---|---|
| Hemoglobin | 0 | 1 | 1 | 0 | 0 | 0 |
| Creatine Kinase | 5 | 7 | 12 | 1 | 0 | 1 |
| LDL Cholesterol | 7 | 6 | 13 | 2 | 5 | 7 |
| LDL Cholesterol, fasting | 4 | 1 | 5 | 1 | 3 | 4 |
| LDL Cholesterol, not fasting | 0 | 3 | 3 | 0 | 1 | 1 |
| Potassium, high | 0 | 0 | 0 | 3 | 0 | 3 |
| Triglycerides | 1 | 0 | 1 | 0 | 0 | 0 |
| Urinalysis | 1 | 0 | 1 | 0 | 0 | 0 |
AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. AEs included both SAEs and all non-SAEs. Severity: Moderate=Alleviated with additional specific therapeutic intervention, interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe= Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.
| Participants | Zavegepant 100 mg (OLE) | Zavegepant 200 mg (OLE) |
|---|---|---|
| Number of Participants With Moderate or Severe AEs: OLE Phase | 29 | 37 |
AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.
| Participants | Zavegepant 100 mg (OLE) | Zavegepant 200 mg (OLE) |
|---|---|---|
| Number of Participants With SAEs: OLE Phase | 1 | 3 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
| Participants | Zavegepant 100 mg (OLE) | Zavegepant 200 mg (OLE) |
|---|---|---|
| Number of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase | 2 | 4 |
Laboratory tests included eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets; albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, bilirubin, calcium, cholesterol, potassium, sodium, triglycerides, uric acid, urinalysis, urine protein, creatine kinase (CK), creatinine, glomerular filtration rate (GFR), glucose, glucose fasting, lactate dehydrogenase, low density lipoprotein (LDL) Cholesterol, LDL Cholesterol. Number of participants with grade 3 to 4 laboratory test abnormalities were evaluated in this outcome measure. Only rows which included at least 1 participant in any reporting group with grade 3 to 4 abnormality were reported in this outcome measure. As per Common Terminology Criteria for Adverse Events (CTCAE version 5.0) Grade 3= severe and Grade 4= life-threatening or disabling.
| Participants | Zavegepant 100 mg (OLE) | Zavegepant 200 mg (OLE) |
|---|---|---|
| Hemoglobin | 0 | 1 |
| Neutrophils | 1 | 1 |
| AST | 0 | 1 |
| Creatine Kinase | 10 | 7 |
| Glucose fasting, low | 1 | 0 |
| LDL Cholesterol | 7 | 8 |
| LDL Cholesterol, fasting | 4 | 4 |
| LDL Cholesterol, not fasting | 1 | 1 |
| Potassium, high | 0 | 2 |
| Triglycerides | 1 | 1 |
| Triglycerides, fasting | 0 | 1 |
| Triglycerides, not fasting | 1 | 0 |
| Urinalysis | 1 | 0 |
Elevations of AST or alanine aminotransferase (ALT) \> 3 \*upper limit of normal (ULN) concurrent with total bilirubin (TBL) \> 2 \*ULN (elevations on the same laboratory collection date) were included.
| Percentage of participants | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Zavegepant Pooled (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Placebo Pooled (DBT) |
|---|---|---|---|---|---|---|
| Percentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: DBT Phase | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) | 0 (0.0 to 1.3) | 0 (0.0 to 5.0) | 0 (0.0 to 4.9) | 0 (0.0 to 2.5) |
Elevations of AST or ALT \> 3 \* ULN concurrent with TBL \> 2 \*ULN were defined as elevations on the same collection date.
| Percentage of participants | Zavegepant 100 mg (OLE) | Zavegepant 200 mg (OLE) |
|---|---|---|
| Percentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: OLE Phase | 0 (0.0 to 2.8) | 0 (0.0 to 3.0) |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. AEs by intensity: Mild: Transient and may require only minimal treatment or therapeutic intervention. Event did not interfere with activities of daily living. Moderate: Alleviated with additional specific therapeutic intervention. Event interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe: Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.
| Participants | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Zavegepant Pooled (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Placebo Pooled (DBT) |
|---|---|---|---|---|---|---|
| Mild | 1 | 0 | 1 | 1 | 0 | 1 |
| Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Severe | 0 | 0 | 0 | 0 | 0 | 0 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
| Participants | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Zavegepant Pooled (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Placebo Pooled (DBT) |
|---|---|---|---|---|---|---|
| Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: DBT Phase | 0 | 0 | 0 | 0 | 0 | 0 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. AEs by intensity: Mild: Transient and may require only minimal treatment or therapeutic intervention. Event did not interfere with activities of daily living. Moderate: Alleviated with additional specific therapeutic intervention. Event interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe: Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.
| Participants | Zavegepant 100 mg (OLE) | Zavegepant 200 mg (OLE) |
|---|---|---|
| Mild | 1 | 1 |
| Moderate | 1 | 2 |
| Severe | 0 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
| Participants | Zavegepant 100 mg (OLE) | Zavegepant 200 mg (OLE) |
|---|---|---|
| Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: OLE Phase | 0 | 1 |
Collected over DBT Phase: 12 weeks of treatment; OLE Phase: 52 weeks of treatment; Follow-up phase: 8 weeks after the discontinuation or completion of treatment in DBT (if not entered OLE) or OLE phase. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zavegepant 100 mg (DBT) | 1/173 (0.6%) | 1/173 (0.6%) | 14/173 (8.1%) |
| Zavegepant 200 mg (DBT) | 0/175 (0%) | 1/175 (0.6%) | 8/175 (4.6%) |
| Zavegepant Pooled (DBT) | 0/348 (0%) | 2/348 (0.6%) | 22/348 (6.3%) |
| Placebo (DBT) Matched to Zavegepant 100 mg | 0/86 (0%) | 0/86 (0%) | 13/86 (15.1%) |
| Placebo (DBT) Matched to Zavegepant 200 mg | 0/88 (0%) | 1/88 (1.1%) | 11/88 (12.5%) |
| Placebo Pooled (DBT) | 0/174 (0%) | 1/174 (0.6%) | 24/174 (13.8%) |
| Zavegepant 100 mg (OLE) | 0/155 (0%) | 1/155 (0.6%) | 12/155 (7.7%) |
| Zavegepant 200 mg (OLE) | 0/143 (0%) | 3/143 (2.1%) | 12/143 (8.4%) |
| Zavegepant 100 mg DBT/Zavegepant 100 mg OLE: Follow-up | 0/154 (0%) | 0/154 (0%) | 0/154 (0%) |
| Zavegepant 200 mg DBT/ Zavegepant 200 mg OLE: Follow-up | 0/162 (0%) | 1/162 (0.6%) | 0/162 (0%) |
| Placebo Matched to Zavegepant 100 mg (DBT)/ Zavegepant 100 mg OLE: Follow-up | 0/47 (0%) | 1/47 (2.1%) | 0/47 (0%) |
| Placebo Matched to Zavegepant 200 mg (DBT)/ Zavegepant 200 mg OLE: Follow-up | 0/48 (0%) | 0/48 (0%) | 0/48 (0%) |
| Placebo Pooled (DBT)/No Zavegepant OLE: Follow-up | 0/70 (0%) | 0/70 (0%) | 0/70 (0%) |
| Event | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Zavegepant Pooled (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Placebo Pooled (DBT) | Zavegepant 100 mg (OLE) | Zavegepant 200 mg (OLE) | Zavegepant 100 mg DBT/Zavegepant 100 mg OLE: Follow-up | Zavegepant 200 mg DBT/ Zavegepant 200 mg OLE: Follow-up | Placebo Matched to Zavegepant 100 mg (DBT)/ Zavegepant 100 mg OLE: Follow-up | Placebo Matched to Zavegepant 200 mg (DBT)/ Zavegepant 200 mg OLE: Follow-up | Placebo Pooled (DBT)/No Zavegepant OLE: Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/173 | 0/175 | 0/348 | 0/86 | 0/88 | 0/174 | 0/155 | 0/143 | 0/154 | 0/162 | 1/47 | 0/48 | 0/70 |
| CholecystitisHepatobiliary disorders | 0/173 | 0/175 | 0/348 | 0/86 | 0/88 | 0/174 | 0/155 | 2/143 | 0/154 | 0/162 | 0/47 | 0/48 | 0/70 |
| COVID-19Infections and infestations | 0/173 | 0/175 | 0/348 | 0/86 | 1/88 | 1/174 | 0/155 | 0/143 | 0/154 | 0/162 | 0/47 | 0/48 | 0/70 |
| Intestinal obstructionGastrointestinal disorders | 0/173 | 0/175 | 0/348 | 0/86 | 0/88 | 0/174 | 0/155 | 1/143 | 0/154 | 0/162 | 0/47 | 0/48 | 0/70 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 0/173 | 0/175 | 0/348 | 0/86 | 0/88 | 0/174 | 0/155 | 1/143 | 0/154 | 0/162 | 0/47 | 0/48 | 0/70 |
| NephrolithiasisRenal and urinary disorders | 0/173 | 0/175 | 0/348 | 0/86 | 0/88 | 0/174 | 1/155 | 0/143 | 0/154 | 0/162 | 0/47 | 0/48 | 0/70 |
| Intervertebral disc disorderMusculoskeletal and connective tissue disorders | 0/173 | 0/175 | 0/348 | 0/86 | 0/88 | 0/174 | 0/155 | 0/143 | 0/154 | 1/162 | 0/47 | 0/48 | 0/70 |
| Hypertensive heart diseaseCardiac disorders | 1/173 | 0/175 | 1/348 | 0/86 | 0/88 | 0/174 | 0/155 | 0/143 | 0/154 | 0/162 | 0/47 | 0/48 | 0/70 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/173 | 1/175 | 1/348 | 0/86 | 0/88 | 0/174 | 0/155 | 0/143 | 0/154 | 0/162 | 0/47 | 0/48 | 0/70 |
| Event | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Zavegepant Pooled (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Placebo Pooled (DBT) | Zavegepant 100 mg (OLE) | Zavegepant 200 mg (OLE) | Zavegepant 100 mg DBT/Zavegepant 100 mg OLE: Follow-up | Zavegepant 200 mg DBT/ Zavegepant 200 mg OLE: Follow-up | Placebo Matched to Zavegepant 100 mg (DBT)/ Zavegepant 100 mg OLE: Follow-up | Placebo Matched to Zavegepant 200 mg (DBT)/ Zavegepant 200 mg OLE: Follow-up | Placebo Pooled (DBT)/No Zavegepant OLE: Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 12/173 | 5/175 | 17/348 | 8/86 | 5/88 | 13/174 | 0/155 | 0/143 | 0/154 | 0/162 | 0/47 | 0/48 | 0/70 |
| COVID-19Infections and infestations | 0/173 | 0/175 | 0/348 | 0/86 | 0/88 | 0/174 | 12/155 | 12/143 | 0/154 | 0/162 | 0/47 | 0/48 | 0/70 |
| Urinary tract infectionInfections and infestations | 2/173 | 1/175 | 3/348 | 6/86 | 1/88 | 7/174 | 0/155 | 0/143 | 0/154 | 0/162 | 0/47 | 0/48 | 0/70 |
| DiarrhoeaGastrointestinal disorders | 1/173 | 2/175 | 3/348 | 1/86 | 5/88 | 6/174 | 0/155 | 0/143 | 0/154 | 0/162 | 0/47 | 0/48 | 0/70 |
DBT safety analysis set included participants in the safety analysis set who took greater than or equal to (\>=) 1 dose of DB study drug (zavegepant or placebo), i.e., nonmissing DB study drug start date.
| Age, Continuous(Years) | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 41.7 ± 12.85 | 43.2 ± 13.30 | 41.7 ± 13.15 | 41.5 ± 13.14 | 42.2 ± 13.09 |
| Sex: Female, Male(Participants) | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Total |
|---|---|---|---|---|---|
| Female | 127 | 144 | 72 | 70 | 413 |
| Male | 46 | 31 | 14 | 18 | 109 |
| Ethnicity (NIH/OMB)(Participants) | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 48 | 47 | 26 | 27 | 148 |
| Not Hispanic or Latino | 125 | 128 | 60 | 61 | 374 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Zavegepant 100 mg (DBT) | Zavegepant 200 mg (DBT) | Placebo (DBT) Matched to Zavegepant 100 mg | Placebo (DBT) Matched to Zavegepant 200 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 4 | 2 | 3 | 5 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 0 | 1 | 3 |
| Black or African American | 35 | 35 | 16 | 17 | 103 |
| White | 130 | 132 | 66 | 63 | 391 |
| More than one race | 4 | 4 | 1 | 0 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
Showing the first 100 of 116 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2021 to primary completion in Mar 2024, 35 months.
Results were first posted in Mar 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zavegepant